New Admissions and Asymptomatic TB Cases fuel TB Epidemic in Prisons, a Cross Sectional Survey in Tanzania

Chacha David Mangu^{1†}, Petra Clowes^{1,6}, Jan van den Hombergh², Clement
Mwakabenga¹, Simeon Mwanyonga¹, Jane Ambindwile¹, Faith Kayombo¹, Monica
Minja¹, Samuel Kalluvya³, Lisa Gerwing-Adima^{3,4}, Christa Kasang⁴, Andreas Mueller⁴,
Edward Chilolo², Juma Angolwisye⁵, Dickson Nsajigwa⁵, Adili Kachima⁵, Deus Kamala⁶,
Beatrice Mutayobya⁶, Nyanda Elias Ntinginya¹, Michael Hoelscher^{7,8}, Elmar Saathoff^{7,8}
and Andrea Rachow^{7,8}

9 Author's Affiliations

- 10 1. National Institute for Medical Research, Mbeya Medical Research Center, Tanzania
- 11 2. PharmAccess International, Tanzania
- 12 3. Bugando Medical Centre, Mwanza, Tanzania
- 13 4. Medical Mission Institute, Wuerzburg, Germany
- 14 5. Ministry of Home Affairs; Prison Authority
- 15 6. National TB and Leprosy Program, Tanzania
- 7. Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich,
 Germany
- 18 8. German Center for Infection Research (DZIF), Partner Site Munich, Germany

19 **†Corresponding Author**

20 Email: <u>cmangu@nimr-mmrc.org</u>, +255713238757.

21 ABSTRACT

22 Background

There is an increased risk for tuberculosis (TB) infection and disease progression in prison settings. TB prevalence in prisons of high and middle/low income countries have been measured to be between 5 and 50 -times higher than in the general population.

26 Methods

We performed TB active case finding in five central prisons, Keko, Segerea, Ukonga, Butimba and Ruanda prison in Tanzania, using the Xpert MTB/RIF[®] assay on early morning or spot sputum sample from inmates and new entries between April 2014 and July 2015.

31 Results

Out of 13,868 prisoners tested, 13,763 had valid results. TB prevalence was 1.55% 32 33 (214/13,763); new admissions contributed to the majority (61.68%) of TB cases, but prevalence was higher among inmates (1.75%) compared to new admissions (1.45%). 34 35 Ukonga, an urban prison which incarcerates long-term convicted inmates had the highest prevalence of 4.02%. Male gender (OR=2.51, p<0.001), repeated incarcerations 36 37 (OR=2.85, p<0.001), history of TB treatment (OR=1.78, p =0.002), TB symptoms (OR=2.78, p=0.006) and HIV infection (OR=2.86, p=0.002) were associated with 38 39 positive TB results.

40 Conclusion

New admissions could be the driving force of the TB epidemic in the penitentiary
system. However, prison environments remain a major risk factor for developing active
TB disease.

44

45 **INTRODUCTION**

Despite the efforts to reduce the global burden of TB, it has been one of the infectious 46 47 diseases causing substantial morbidity and mortality especially in Asia and Sub-Saharan Africa^{1, 2}. It is estimated that 10.6 million people developed TB in 2021, 25% of 48 49 which occurred in Africa and caused 1.6 million deaths³. TB remains one of the major causes of death among people living with HIV (PLHIV) causing 187,000 deaths in 2021 50 51 ³. TB cases are still under-reported; approximately 6.4 million cases (only 60.4% of global estimated cases) were diagnosed and notified in 2021³. The majority of missed 52 53 TB cases most likely occur among people who lack free or direct access to health care 54 services such as prisoners and people incarcerated. Worldwide, it is estimated that more than 9 million people are incarcerated at any point in time², and therefore faced 55 with a high risk environment for new TB infection and fastening the progression of latent 56 to active TB which, among others, is promoted by overcrowding, poor ventilation and 57 58 poor diet ^{4, 5}. Limited access to health care services results in late case detection and delayed treatment initiation with potential poor adherence sustaining the ongoing TB 59 transmission in prisons ^{4, 5}. 60

61 Despite its highly endemic nature, prevalence of TB in prisons is largely unknown in 62 many countries. Systematic reviews showed incidences of 237.6 per 100,000 and 63 1,942.8 per 100,000 person-years in high and middle/low-income countries, respectively^{6, 7}. Some studies have shown TB rates among inmates as high as 5 to 50 64 times greater than those of the general population across developed and developing 65 countries, respectively⁸. Active mass screening studies in Malawi, Ivory Coast, Zambia, 66 67 Botswana, Cameroon and Ethiopia, found TB prevalence among prisoners of about 7 to more than 10 times higher than in the general population⁹⁻¹⁴. In Tanzania, a study at 68 69 Bugando Hospital, Mwanza, showed a proportion of 41% of smear-positive TB cases among prisoners with presumptive TB referred for diagnosis¹⁵. 70

71

Despite the high TB prevalence and complexity that exists in the control of tuberculosis in prisons, TB detection in most prisons still rely on symptomatic screening¹⁶, however with the availability of approved molecular diagnostic tests, such as GeneXpert, which are more sensitive, easy to perform and rapid, the systematic TB screening in a large

number of persons within a short time has been made possible¹⁹. The aim of this study
was to implement a screening strategy to actively detect TB in five central prisons in
Tanzania mainland using GeneXpert MTB/RIF and accurately measure the prevalence,
and understand the related risk factors of TB in prisons.

80

81 **METHODS**

82 Prisons and study groups

The project was implemented in five central prisons in Tanzania; Keko, Segerea and 83 84 Ukonga Prisons within the highly populated business capital of the Indian Ocean coast region Dar es Salaam; Butimba Prison in Northwest region, Mwanza; and Ruanda 85 Prison in the Southern Highland region, Mbeya. All prisons are located in urban settings 86 87 but admit prisoners from both urban and rural communities. According to the Tanzanian 88 prison authority, during the study period, these prisons housed an average of about 8,000 inmates in total and have a turnover of more than 15,000 new admissions and 89 90 discharges per year. TB screening was done among those who newly entered the prison, were transferred in from another prison and inmates present in the prisons at the 91 92 beginning of the study.

93 Study procedures

94 The project was implemented between April 2014 and June 2015. A screening 95 questionnaire administered by trained prison health staffs. was used to collect demographic information, date of entry into prison, history of previous imprisonment, 96 97 number of inmates sharing a cell, presence of cell mate(s) treated for TB, TB symptoms, self-reported past history of TB treatment, self-reported HIV status and use 98 99 of anti-retroviral treatment (ART). One spontaneously expectorate sputum sample was 100 collected from all study participants by a trained prison health facility staff, a nurse or 101 laboratory technician. TB diagnosis was done using the GeneXpert MTB/RIF[®] assay 102 (Xpert; Cepheid, Sunnyvale, California, US), which was stationed at each prison health 103 facility and operated by trained laboratory technicians who were also prison staff. In case of a failed test ("error", "invalid" or "no result"), Xpert testing was repeated on the 104 105 same sample or a newly collected sample if the sample was either inadequate,

discarded or of poor quality. For those consented for HIV testing, HIV diagnosis was
done according to the national guidelines using SD Bioline HIV-1/2 3.0 (Standard
Diagnostics, Inc. Yongin, South Korea), and confirmed by Alere Determine HIV-1/2
(Alere Inc. Massachusetts, USA) and Uni-Gold HIV-1/2 (Trinity Biotech, Co. Wicklow,
Ireland).

111 Ethical consideration

The study obtained ethical clearance from the National Health Research and Ethics Committee of the National Institute for Medical Research, Tanzania. It was also approved by the Prison Headquarters as well as the National TB and Leprosy Program in Tanzania.

Screening was voluntary; prisoners consented to participate and thumb printed the informed consent form before study procedures were done. HIV diagnosis was done through provider initiated testing and counseling (PITC) by a nurse counselor. Prisoners who refused to test for HIV were not excluded from TB screening. Those diagnosed to have TB or HIV were linked to care at the respective prison health facilities. Only prisoners 18 years and above were included in the study.

122 Statistical analysis

The main endpoint of this study was bacteriologically confirmed TB diagnosed by Xpert.
 Univariate analysis was performed to describe the study population of screened
 prisoners and the prevalence of TB in different strata of the independent variables.

126 A conceptual frame work (Fig. 1) was established to guide multivariable logistic regression analysis in three levels. Variables with a p-value of <0.1 were retained and 127 128 used to adjust for variables in the subsequent level and retained in the last model; and variables in the last model with the p-value of <0.05 were considered significant risk 129 130 factors for TB in prisons. Variables considered distal to the outcome and those proximal 131 to the outcome were in the first and last levels respectively. Number of cell mates was 132 forced into the final model due to its importance in assessing overcrowding within prison 133 cells. Robust standard errors were used in logistic regression to account for correlation 134 within prisons. The Wald test was used to assess significance of the contribution of

- each variable to the model. Data analysis was performed using Stata/SE version 14
- 136 (Stata Corporation, College Station, Texas, US).

Figure 1. Hypothesized conceptual framework to guide model building for multivariate analysis

139

140 **RESULTS**

A total of 16,132 prisoners from 5 central prisons agreed to participate in the study and completed the questionnaire. Of these, 13,868 prisoners were screened using Xpert, of which 105 had either an invalid or erroneous final result. Thus, the final analysis included 13,763 prisoners with valid Xpert result.

145 Baseline characteristics

Of the 13,763 prisoners, majority (96.3%, n=13,248) were male. The median age of screened prisoners was 30 years (IQR 24–36 years) while 64.7% were younger than 35 years. A total of 9,077 (66.0%) prisoners screened were new admissions and 12,035 (87.4%) were in prison for the first time. The median duration of incarceration was 1.5 months at the time point of study participation and sharing a cell with more than 10 inmates was common (93.8%, n=12,911). More than half (51.6%, n=7,106) had unknown HIV status, and 6.1% (n=833) were HIV positive (Table 1).

153

Characteristics Categories Total Prisoners with Prevalence of P-value* (col%) tuberculosis Tuberculosis in % [N=13,763] (col%) [N=214] Female 515 (3.7) 4(1.9)0.78 0.150 Sex Male 13,248 (96.3) 210 (98.1) 1.59 <25 3,731 (27.1) 35 (16.4) 0.94 25-34 5,177 (37.6) 87 (40.7) 1.68 0.004 Age in years 35-44 3,030 (22.0) 58 (27.1) 1.91 >45 1,825 (13.3) 34 (15.9) 1.86 New Admission 9,077 (66.0) 132 (61.7) 1.45 0.184 **Prisoner Status** Inmate 4,686 (34.0) 82 (38.3) 1.75 <6 months 8,643 (62.8) 114 (53.3) 1.32 6-24 months 1,703 (12.4) 37 (17.3) 2.17 Duration of 0.023 24-60 months 1,246 (9.1) 21 (9.8) 1.69 Incarceration >60 months 2,171 (15.8) 42 (19.6) 1.93 163 (76.2) 1 12,035 (87.4) 1.35 Number of < 0.001 2-3 1,573 (11.4) 41 (19.2) 2.61 Incarcerations >4 155 (1.1) 10 (4.7) 6.45 <5 47 (0.3) 2 (0.9) 4.26 0.195 Number of Cell Mates 6-10 805 (5.9) 9 (4.2) 1.12 >10 203 (94.9) 1.57 2,911 (93.8) 13,713 (99.6) 212 (99.1) 1.55 No Known TB contact 0.162 from Cell Mate Yes 50 (0.4) 2 (0.9) 4.00 33 (15.4) 4.95 Yes 666 (4.8) Previously treated for < 0.001 ТΒ No 13,097 (95.2) 181 (84.6) 1.38 Yes 2,261 (16.4) 92 (43.0) 4.07 Reported one or more < 0.001 TB symptoms No 11,502 (83.6) 122 (57.0) 1.06 Negative 5,824 (42.3) 85 (39.7) 1.46 Positive 833 (6.1) 40 (18.7) 4.80 < 0.001 **HIV Status** 1.25 Not Known 7,106 (51.6) 89 (41.6) Ruanda 4520 (32.8) 42 (19.6) 0.98 Butimba 4328 (31.5) 48 (22.4) 1.12 Ukonga 828 (6.0) 32 (15.0) 4.02 < 0.001 Prison ID Keko 1921 (14.0) 26 (12.2) 1.37 0.03 Segerea 2166 (15.7) 66 (30.8)

154 TABLE 1. Characteristics of the study population and TB cases

155 *chi squared test p-value for difference in TB-prevalence between strata

156 Risk factors associated with TB diagnosis

157 In multivariable analysis, males had more than two times the odds for TB infection than 158 females (Odds Ratio [OR] = 2.51, 95% confidence interval [CI] = 1.54 to 4.08, p-value [p] = <0.001). Age did not appear to be an important independent risk factor for active 159 TB. The OR significantly increased with the frequency of incarcerations to nearly three 160 161 times higher odd for active TB in prisoners who have been in prison four or more times (OR=2.85 CI=1.78 to 4.55, p<0.001). Previous history of TB treatment was associated 162 with current active TB disease (OR=1.78, CI=1.24 to 2.55, p=0.002). Participants with 163 164 TB symptoms were three times more likely to test positive for TB than those without symptoms (OR=2.78, CI=1.35 to 5.74, p<0.006) and HIV positive prisoners also had 165 166 significantly higher odds of TB than HIV-negative prisoners (OR=2.86, CI=1.49 to 5.52, 167 p=0.002). Being incarcerated in prisons located in the business capital, Ukonga prison (which admits convicted offenders) or Segerea prison (which admits new remandees) 168 169 was associated with a two times higher OR for having TB (OR= 2.15, CI 1.63 to 2.83, p<0.001 and OR=2.10, CI 1.75 to 2.52, p<0.001 respectively). Sharing a cell with more 170 171 than 10 people was not associated with TB infection (Table 2).

172 TABLE 2. Association of various factors with TB disease (N = 13,763; n= 214 (1.555%): Uni-

173 and multi-variable logistic regression results; using robust variance estimates adjusted for

174 clustering by PrisonID.

					Univariable			Multivariable	
						p-			p-
Covariate	N	n	%	OR	95% CI	value	OR	95% CI	value
Sex									
Female*	515	4	0.777	1.00	-	-	1.00	-	-
Male	13,248	210	1.585	2.06	(1.03 to 4.11)	0.041	2.51	(1.54 to 4.08)	<0.001
agegroup									
< 25 yrs*	3,731	35	0.938	1.00	-	-	1.00	-	-
25 - <35 yrs	5,177	87	1.681	1.80	(1.49 to 2.19)	<0.001	1.31	(0.97 to 1.78)	0.083
35 - <45 yrs	3,030	58	1.914	2.06	(1.33 to 3.20)	0.001	1.28	(0.75 to 2.21)	0.365
>=45 yrs	1,825	34	1.863	2.00	(0.98 to 4.11)	0.058	1.30	(0.70 to 2.42)	0.399
Number of									
Incercerations									
1*	12,035	163	1.354	1.00	-	-	1.00	-	-
2-3	1,573	41	2.606	1.95	(1.15 to 3.31)	0.013	1.57	(1.17 to 2.09)	0.002
<u>></u> 4	155	10	6.452	5.02	(2.57 to 9.81)	<0.001	2.85	(1.78 to 4.55)	<0.001
Duration of									
Incarceration									
<=6 months*	8,643	114	1.319	1.00	-	-	1.00	-	-
6 - 24 months	1,703	37	2.173	1.66	(1.35 to 2.05)	<0.001	1.31	(1.07 to 1.62)	0.010
24 - 60 months	1,246	21	1.685	1.28	(0.79 to 2.09)	0.318	0.87	(0.61 to 1.22)	0.414
>60 months	2,171	42	1.935	1.48	(0.72 to 3.05)	0.292	0.95	(0.77 to 1.18)	0.669
HIV Result									
Negative*	5,824	85	1.459	1.00	-	-	1.00	-	-
Positive	833	40	4.802	3.41	(1.68 to 6.89)	<0.001	2.86	(1.49 to 5.52)	0.002
Unknown	7,106	89	1.252	0.86	(0.67 to 1.09)	0.214	1.18	(0.86 to 1.61)	0.314
History of TB									
Treatment	40.007	404	4 000	4 00			4 0 0		
No*	13,097	181	1.382	1.00	-	-	1.00	-	-
Yes	666	33	4.955	3.72	(2.87 to 4.82)	<0.001	1.78	(1.24 to 2.55)	0.002
Number of Cell Mates									
<10*	852	11	1.291	1.00	-	_	1.00	_	_
>10	12,911	203	1.572	1.22	(0.89 to 1.68)	0.216	0.93	(0.74 to 1.18)	0.570
Any TB	12,011	200	1.072	1.22	(0.00 10 1.00)	0.210	0.00	(0.7 1 10 1.10)	0.010
Symptoms									
No*	11,502	122	1.061	1.00	-	-	1.00		-
Yes	2,261	92	4.069	3.96	(2.13 to 7.35)	<0.001	2.78	(1.35 to 5.74)	0.006
PrisonID	,								
Ruanda*	4,520	42	0.929	1.00		-	1.00		-
Butimba	4,328	48	1.109	1.20	(1.20 to 1.20)	<0.001	1.10	(1.02 to 1.20)	0.019
Ukonga	828	32	3.865	4.29	(4.29 to 4.29)	< 0.001	2.15	(1.63 to 2.83)	< 0.001
Keko	1,921	26	1.353	1.46	(1.46 to 1.46)	< 0.001	1.08	(1.01 to 1.15)	0.027
Segera	2,166	66	3.047	3.35	(3.35 to 3.35)	< 0.001	2.10	(1.75 to 2.52)	<0.001
N = number of observations; n = number of positives; % = percent positive; 95% CI = 95% confidence interval									

N = number of observations; *n*= number of positives; %= percent positive; 95% CI = 95% confidence interval * reference stratum

175 **DISCUSSION**

Our findings show a high TB burden in Tanzania prisons. The prevalence of bacteriologically confirmed TB of 1.55% (1,550 cases/100,000 population) is more than 5 times higher than the prevalence in the general population of 295 per 100,000¹⁸.

179 Our study contributes important findings over the containment of asymptomatic TB 180 cases in prison settings. Sustained and prolonged exposure to TB bacilli could be 181 maintained in prison walls by asymptomatic cases and can potentially propagate TB 182 transmission among inmates if conventional symptomatic TB screening is the only 183 screening method relied on since studies have shown that asymptomatic TB cases have the ability to infect others^{16,19-20}. For this reason robust and effective approaches 184 using effective diagnostic tools for TB screening in prisoners are required. Nonetheless, 185 TB symptoms remain a major predictor of TB disease as shown by a TB high 186 187 prevalence in prisoners with symptoms compared to those without (4.07% vs 1.06% respectively). Therefore an effective screening intervention is the one that apply mixed 188 189 methods that detect both symptomatic and asymptomatic TB.

190 Despite high TB prevalence among inmates, the fact that 61% of detected TB cases in this study were among new admissions suggests that new admissions bring TB into the 191 192 prison facilities and therefore contribute significantly to the TB epidemic in prisons. These findings also observed in other studies^{21, 22} in countries with high TB burden 193 194 suggests two possible explanations; firstly, many of those who commit offenses and end 195 up in a penal institution come from a background of high risk for TB infection and therefore bring with them an increased risk for TB infection into prison and actively 196 197 contribute to the high prevalence of TB in prisons⁵. And secondly, it is highly likely that 198 specific conditions in prisons lead to a higher risk of TB infection and accelerate latent 199 TB infections to progress to active disease within a short duration of time. Many TB 200 control strategies in prisons focus on already incarcerated inmates while little or no 201 attention is given to new admissions. Findings from our study suggest that equal weight 202 has to be given to both groups of prisoners. Constant screening at prison-entry aims at 203 detecting untreated admissions and thereby reduce introduction of new TB cases into

prison while mass and contact screening should aim at detecting the circulating TB
 within the prison walls²³.

206 Our findings do not suggest overcrowding to be a risk factor for TB disease in prison; 207 however, this might be due to the possibility that the disaggregation by number of 208 inmates per cell during data collection was not specific enough and hence it probably 209 obscures the association. Similarly, having a known TB contact within the cells was not 210 associated with TB infection in our study, however, this finding could be due to the fact 211 that more than 50% of the identified TB cases were new entries who didn't have 212 prolonged contact with other inmates during the time of screening. Yet, screening of 213 individuals who have contact with index cases should still continue as recommended 214 because it is effective in increasing case detection^{23, 24, 25}. HIV remains an important 215 single predictor of TB infection in prison settings as it is well known to fuel the TB 216 epidemic²⁶. Notably, effective control of TB infection also requires appropriate 217 interventions against HIV infection.

218

219 CONCLUSION AND RECOMMENDATIONS

220 Our study showed a high TB burden in Tanzanian prisons. The majority of positive TB 221 tests was among symptomatic prisoners, new entries and inmates who stayed only for a 222 short time in prison. Other TB risk factors were not prison-associated. Prisoners remain 223 a high risk population with great mobility due to perpetuating referrals between prisons and interactions with the outside communities; our results suggest that TB screening 224 225 measures within prisons need to be sensitive, robust and with a fast enough turn-over 226 time to combat TB in prisoners and consequently interrupt TB transmission not only in 227 prisons but also in the surrounding communities.

TB screening on admission or exit for both remandees and inmates using WHO recommended PCR based rapid diagnostics such as GeneXpert was not a routine practice in Tanzania prisons at the time of this study. However, because of the findings of this study, active TB screening on all prison entry points have been implemented in

Tanzania ever since. Future research is needed to assess the impact of the implementation of WHO approved rapid TB diagnostic tools in prison settings.

234

235 Acknowledgements

236 We acknowledge the effort from all collaborating institutions implementing the study, NIMR-Mbeya Centre, Tanzania (project lead); PharmAccess International, Tanzania; 237 238 Medical Mission Institute of Wuerzburg, Germany; Bugando Referral Hospital, 239 Tanzania; Division of Infectious Diseases and Tropical Medicine, University of Munich 240 (LMU) Germany (grant holder). We thank the Tanzania Prison Authority Headquarter, 241 and the National TB and Leprosy Program for facilitating study activities. To all the prison health staffs for your dedication and prisoners for your participation, we thank 242 243 you.

244

245 Conflicts of interests

246 Authors declare no conflict of interest.

247 Funding

The project was funded by the WHO, STOP TB Partnership through the TB REACH funding initiative.

Authors Contribution

251 CDM, PC, MH, AR designed the study, applied for grant, supervised study 252 implementation, and reviewed the manuscript.

253 CDM, ES performed data analysis.

JH, CM, JA, FK, MM, SK, LG, CK, AM, DK, & NE reviewed the study design, coordinated and supervised study implementation, and reviewed the manuscript;

256 CDM wrote the manuscript

257 **References**

- 1. Dye C. Global Epidemiology of tuberculosis. *Lancet* 2006; 367:938-40.
- Dye C, Lönnroth K, Jaramillo E, Williamsa BG, and Raviglionea M. Trends in tuberculosis incidence and their determinants in 134 countries. *Bulletin of the World Health Organization*. 2009; 87(683-691):
- WORLD HEALTH ORGANIZATION *Global Tuberculosis Report 2022.* ISBN 978 92-4-001313-1. WHO Press, Geneva, 2020. 1-208.
- Dara M, Acosta CD, Melchers NV, Al-Darraji HA, Chorgoliani D, Reyes H, et al.
 Tuberculosis control in prisons: current situation and research gaps. *Int J Infect Dis.* 2015 Mar; 32:111-7.
- 267 5. Reyes HN. Pitfalls of TB Management in Prisons, Revisited. *International Journal* 268 of Prisoner Health, 2007; 3(1).43-67
- 2696. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis270Incidence in Prisons: A Systematic Review. PLoS Med 2010: 7(12): e1000381.271Availablefrom:
- https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000381
- 273 7. WOLRD HEALTH ORGANIZATION. Literature Review on Tuberculosis in
 274 Prisons. Geneva, WHO 2008: 1-16
- THE PLoS MEDICINE EDITORS. The Health Crisis of Tuberculosis in Prisons
 Extends beyond the Prison Walls. *PLoS Med* 2010: 7(12): Available from:
 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000383
- 9. Nyangulu DS, Harries AD, Kangombe C, Yadidi AE, Chokani K, Culliana T, et al.
 Tuberculosis in a prison population in Malawi. *The Lancet*. 1997; 350(9087).
 1284-7.
- 10. Koffi N, Ngom AK, Aka-Danguy E, Seka A, Akoto A, Fadiga D. Smear positive
 pulmonary tuberculosis in a prison setting: Experience in the penal camp of
 Bouake, Ivory Coast. *Int J Tuberc Lung Dis.* 1997; 1(3).250-3.
- 11. Habeenzu C, Mitarai S, Lubasi D, Mudenda V, Katenga T, Mwansa J, et al.
 Tuberculosis and multidrug resistance in Zambian prisons, 2000-2001. *Int J Tuberc Lung Dis*. 2007 Nov; 11(11):1216-20

- 12. Noeske J, Kauban C, Amougou G, Pibello A, Poillot R. Pulmonary tuberculosis in
 the Central Prison of Douala, Cameroon. *East Afr Med J.* 2006; 83(1):25-30
- 13. Abebe DS, Bjune G, Ameni G, Biffa D, Abebe F. Prevalence of pulmonary
 tuberculosis and associated risk factors in Eastern Ethiopian prisons. *Int J Tuberc Lung Dis.* 2011; 15(5):668-73.
- 14.O'Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, et al.
 Tuberculosis in prisons in sub-Saharan Africa the need for improved health
 services surveillance and control. *Elesevier* 2010; 10(12):1-6.
- 29515. Rutta E, Mutasigwa D, Ngallba S, Mwansasu A. Tuberculosis in a prison296population in Mwanza, Tanzania. Int J Tuberc Lung Dis. 2001; 5(8):703-6.
- 16. Reid ES, Topp SE, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, et al.
 Tuberculosis and HIV Control in Sub-Saharan African Prisons: "Thinking Outside
 the Prison Cell". *J Infect Dis.* 2012; 205(Suppl 2): S265-73
- 17.WORLD HEALTH ORGANIZATION. Consolidated guidelines on tuberculosis.
 Module 3: diagnosis-rapid diagnostics for tuberculosis detection, 2021 update.
 Geneva: World Health Organization; 2021. 1-137
- 18. UNITED REPUBLIC OF TANZANIA, MINISTRY OF HEALTH AND SOCIAL
 WELFARE. The First National Tuberculosis Prevalence Survey in the United
 Republic of Tanzania, Final Report. Dar Es Salaam, [publisher unknown], 2013.
 1-156
- 307 19. Shaw JB, Ynn-Williams N. Infectivity of pulmonary tuberculosis in relation to
 308 sputum status. *Am. Rev. Tuberc.* 1954; **69:**724–32.
- 20. Tostmann A, Kik VS, Lakisvaart AN, Sebek MM, Verver S, Boeree JM, et al.
 Tuberculosis Transmission by Patients with Smear-Negative Pulmonary
 Tuberculosis in a Large Cohort in The Netherlands. *Clin Infect Dis.* 2008; 47
 (9):1135-42.
- 21. Moges B, Amare B, Asfaw F, Tesfaye W, Tiruneh M, Belyhun Y, et al.
 Prevalence of smear positive pulmonary tuberculosis among prisoners in North
 Gonder Zone Prison, Northwest Ethiopia. *BMC Infectious Disease* 2012;
 12(352):1471-2334.
- 22. Winetsky DE, Almukhamedov O, Pulatov D, Vezhinina N, Dooronbekova A,
 Zhussupov B. Prevalence, Risk Factors and Social Context of Active Pulmonary

- 319Tuberculosis among Prison Imates in Tajikistan PLoS Med 2014; 9(1): e86046.320Availablefrom:
- 321 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086046
- 23. Dara M, Grzemska M, Kimerling ME, Reyes H and Zagorskiy A. Guidelines for 322 Control of Tuberculosis in Prisons. [Internet] [place unknown] TB CAP 2009. 323 324 24 2014]. Available [Cited: June 4-151. from: 325 https://www.challengetb.org/publications/tools/ua/Guidelines for control of TB i 326 n prisons.pdf
- 327 24.WORLD HEALTH ORGANISATON. WHO consolidated guidelines on
 328 tuberculosis. Module 2: screening systematic screening for tuberculosis
 329 disease. Geneva: World Health Organization; 2021.
- 25. WORLD HEALTH ORGANISATION. Guidelines for the control of tuberculosis in
 prisons. Geneva: World Health Organization; 1998.
- 26. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Fausset P.
 Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with
 Enhanced Diagnosis of Symptomatic Disease. PLoS Med 2007; 4(1): e22.
 Available
- https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040022




Figure 1